ArticleInternational journal of nanomedicine2026
Evaluation of Modified Chitosan Nanomicelles with Carboplatin for Effective Treatment Against Ovarian Cancer Cell Types in Murine Model.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The clinical efficacy of platinum-based chemotherapy in ovarian cancer is limited by insufficient drug retention within the peritoneal cavity and associated systemic toxicity. This study aimed to develop hydrophobically modified chitosan nanomicelles as a carrier system for localized carboplatin delivery. Methods: Hydrophobically modified chitosan nanomicelles were prepared using an oil-in-watr emulsification technique and characterized in terms of their physicochemical properties, stability, encapsulation efficiency, and drug release behaviour. In vitro studies were performed to assess biocompatibility and cellular internalization in MUC1-expressing SK-OV-3 ovarian cancer cells. The preliminary in vivo antitumour response to the carboplatin-loaded nanomicelles was further evaluated in a subcutaneous murine ovarian cancer xenograft model. Results: The obtained nanomicelles exhibited a mean hydrodynamic diameter of approximately 200 nm and an encapsulation efficiency of 44%. No quantifiable carboplatin release was detected within 24 h under the tested conditions; however, the absence of a quantifiable signal cannot distinguish limited early release from release below the quantifiable range of the analytical method. The nanomicelles demonstrated preliminary in vitro cytocompatibility in SK-OV-3 cells, with mean cell viability remaining above 70% under the tested conditions, and intracellular localization of the nanomicelles in MUC1-expressing SK-OV-3 cells was observed by confocal microscopy. At the end-point evaluation, tumours were significantly smaller in the nanomicelle-treated group than in the free-carboplatin group (p = 0.03), whereas exploratory longitudinal analysis of tumour-growth AUC showed no significant between-group difference (p = 0.67). Conclusion: Hydrophobically modified chitosan nanomicelles represent a feasible carrier platform for localized carboplatin delivery and warrant further investigation for potential intraperitoneal application. The observed drug encapsulation, lack of quantifiable carboplatin release during the 24-h study period, preliminary in vitro cytocompatibility in SK-OV-3 cells, cellular internalization, and preliminary antitumour response provide proof-of-concept support for continued evaluation of this carrier system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.